glucose, (beta-d)-isomer has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Guo, Q; Liu, J; Sun, H; Wu, Y; Xu, Y | 1 |
| Alvarado, Y; Borthakur, G; Bueso-Ramos, C; Cortes, J; Estrov, Z; Faderl, S; Giles, F; Ivy, P; Nebiyou Bekele, B; Ravandi-Kashani, F | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Hematologic Malignancies
| Article | Year |
|---|---|
Natural products against hematological malignancies and identification of their targets.
Topics: Biological Products; Diterpenes, Kaurane; Flavanones; Glucosides; Hematologic Neoplasms; Humans; Molecular Structure; Molecular Targeted Therapy; Phytotherapy; Xanthones | 2015 |
1 trial(s) available for glucose, (beta-d)-isomer and Hematologic Malignancies
| Article | Year |
|---|---|
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Biopsy; Bone Marrow; Carbazoles; Dose-Response Relationship, Drug; Female; Glucosides; Hematologic Neoplasms; Humans; Male; Middle Aged; Virus Diseases | 2008 |